Basal Cell Carcinoma

Numerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Regeneron and Sanofi’s Checkpoint Inhibitor Shines in Phase II BCC Study

Basal Cell Carcinoma, Business, Checkpoint Inhibitors, Clinical Data, Clinical Trials, European Society for Medical Oncology (ESMO), Hedgehog Pathway Inhibitors, Partnerships, PD-1 Inhibitors, R&D

Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.

Bay Area Startup BridgeBio Quietly Snags $135 Million From a Bunch of Wall Street Firms

Basal Cell Carcinoma, Cardiology, Dermatology, Endocrinology, Genetic Diseases, Gorlin Syndrome, Heart Disorders, Neurology, Oncology, Product Pipelines, TTR Amyloidosis (ATTR)

BridgeBio Pharma, which was founded in 2015, recently closed on a $135 million series C round that was co-led by Viking Global Investors and KKR. They were joined by Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Janus Funds.